title: Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
abstract: This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
authors.affiliation: "Angelo Bianchi Bonomi" Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.
authors.forename: Pier Mannuccio
authors.initials: PM
authors.lastname: Mannucci
authors.affiliation: Department of Transfusion Medicine and Haematology, "Carlo Poma" Hospital, Mantua, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Franchini
mesh_terms: D000818:Animals; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology; D005169:Factor VIII / Q000235:genetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D013552:Swine
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D005169:Factor VIII